Patents by Inventor Robert B. Perni

Robert B. Perni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7241796
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: July 10, 2007
    Assignee: Vertex Pharmaceuticals Inc.
    Inventors: Luc J. Farmer, Robert B. Perni, Janos Pitlik, John H. van Drie, Jr.
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
    Patent number: 7208600
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: April 24, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7109172
    Abstract: The present invention relates to compounds of formula I or formula Ia or pharmaceutically acceptable salts thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: September 19, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Shawn D. Britt, Kevin M. Cottrell, Robert B. Perni, Janos Pitlik
  • Bridged bicyclic serine protease inhibitors
    Patent number: 6909000
    Abstract: The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: June 21, 2005
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Janos Pitlik, Robert B. Perni, Lawrence F. Courtney, John van Drie
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Publication number: 20040018986
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: April 11, 2003
    Publication date: January 29, 2004
    Inventors: Janos Pitlik, Kevin M. Cottrell, Luc J. Farmer, Robert B. Perni, Lawrence F. Courtney, John H. van Drie, Mark A. Murcko
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Publication number: 20030134889
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: October 24, 2002
    Publication date: July 17, 2003
    Inventors: Luc J. Farmer, Robert B. Perni, Janos Pitlik, John H. van Drie
  • Bridged bicyclic serine protease inhibitors
    Publication number: 20030119752
    Abstract: The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: July 11, 2002
    Publication date: June 26, 2003
    Inventors: Luc J. Farmer, Janos Pitlik, Robert B. Perni, Lawrence F. Courtney, John van Drie
  • Benzothiopyranoindazole antitumor agents
    Patent number: 5532263
    Abstract: Novel 2H-[1]benzothiopyrano[4,3,2-cd]indazoles are disclosed as antitumor agents. Compositions containing the benzothiopyranoindazoles and methods of treating tumors and cancer in mammals with benzothiopyranoindazoles are also disclosed.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: July 2, 1996
    Assignee: Sterling Winthrop Inc.
    Inventors: Mark P. Wentland, Robert B. Perni
  • Thioxanthenone antitumor agents
    Patent number: 5380749
    Abstract: 1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones are disclosed as antitumor agents. Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: January 10, 1995
    Assignee: Sterling Winthrop Inc.
    Inventors: Theodore C. Miller, Joseph C. Collins, Kenneth C. Mattes, Mark P. Wentland, Robert B. Perni, Thomas H. Corbett, Joseph W. Guiles
  • Thioxanthenone antitumor agents
    Patent number: 5346917
    Abstract: 1-[[(Dialkylamino)alkyl]amino]-4-substituted-thioxanthen-9-ones are disclosed as antitumor agents. Compositions containing the thioxanthenones and methods of treating tumors and cancer in mammals with the thioxanthenones are also disclosed.
    Type: Grant
    Filed: April 8, 1993
    Date of Patent: September 13, 1994
    Assignee: Sterling Winthrop Inc.
    Inventors: Theodore C. Miller, Joseph C. Collins, Kenneth C. Mattes, Mark P. Wentland, Robert B. Perni, Thomas H. Corbett, Joseph W. Guiles